Rossana Berardi

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Journal: ESMO gastrointestinal oncology

Published: August 28, 2026

Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].

Journal: Cancer treatment and research communications

Published: August 25, 2026

From fragmentation to focus: building collaborative networks for rare cancer research - the Italian TYME network as a model for care and innovation?

Journal: Expert review of anticancer therapy

Published: August 24, 2026

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2026

One Health and Gender Oncology: An Integrated Framework for Equitable Oncology Care Across the Human-Animal-Environment Interfaces.

Journal: Cancers

Published: July 07, 2026

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2026

A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.

Journal: Cancers

Published: June 03, 2026

Gender Oncology: Rethinking Cancer Through a Sex- and Gender-Based Lens.

Journal: Journal of clinical medicine

Published: May 26, 2026

Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Journal: Cancer treatment reviews

Published: May 04, 2026

Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 10, 2026

Sex and gender-oriented colorectal cancer screening: a consensus study from the AIOM- GISEG working group.

Journal: Frontiers in oncology

Published: March 26, 2026

International Consensus on Severe Lung Cancer-The Second Edition.

Journal: Translational lung cancer research

Published: March 21, 2026

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].

Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].

From fragmentation to focus: building collaborative networks for rare cancer research - the Italian TYME network as a model for care and innovation?

From fragmentation to focus: building collaborative networks for rare cancer research - the Italian TYME network as a model for care and innovation?

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

One Health and Gender Oncology: An Integrated Framework for Equitable Oncology Care Across the Human-Animal-Environment Interfaces.

One Health and Gender Oncology: An Integrated Framework for Equitable Oncology Care Across the Human-Animal-Environment Interfaces.

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.

A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.

Gender Oncology: Rethinking Cancer Through a Sex- and Gender-Based Lens.

Gender Oncology: Rethinking Cancer Through a Sex- and Gender-Based Lens.

Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.

Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.

Sex and gender-oriented colorectal cancer screening: a consensus study from the AIOM- GISEG working group.

Sex and gender-oriented colorectal cancer screening: a consensus study from the AIOM- GISEG working group.

International Consensus on Severe Lung Cancer-The Second Edition.

International Consensus on Severe Lung Cancer-The Second Edition.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.